Lower Drug Costs through Competition Act
Latest action · Feb 3, 2017 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJan 30, 2017
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Lower Drug Costs through Competition Act
This bill amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs: (1) for which there is a shortage, or (2) that have not been recently introduced to the market by more than one manufacturer and for which tentative approval has not been granted to more than two applications.
The Food and Drug Administration (FDA) must prioritize the review of such submissions and act on them within 180 days. The FDA may expedite the inspection of a facility proposed to manufacture such a drug.
Beginning FY2019, the FDA must award a transferrable generic drug priority review voucher to the sponsor of such an application once the drug has a sustained market presence. A voucher may be used to have the FDA review and take action upon a generic drug application within 180 days of submission. The FDA must establish an additional user fee for applications subject to a voucher. This voucher program is terminated at the start of FY2024.
The FDA must periodically report on generic drug applications filed before FY2018 that are still pending.
For a new drug application to be eligible for a priority review voucher as a tropical disease product application, the application must include new, essential clinical investigations.
The Government Accountability Office must study the FDA's program for drug risk evaluation and mitigation strategies.Cosponsors 24
Members who signed on, in the order they did. Signatures ran from Jan 30, 2017 to Feb 6, 2018; 9 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-CA | Ami Bera | Original | Jan 30, 2017 |
| R-FL | Bill Posey | Original | Jan 30, 2017 |
| D-IL | Daniel Lipinski | Original | Jan 30, 2017 |
| R-FL | Gus M. Bilirakis | Original | Jan 30, 2017 |
| D-TN | Jim Cooper | Original | Jan 30, 2017 |
| D-CA | Jim Costa | Original | Jan 30, 2017 |
| I-AZ | Kyrsten Sinema | Original | Jan 30, 2017 |
| D-CA | Scott H. Peters | Original | Jan 30, 2017 |
| D-MA | Seth Moulton | Original | Jan 30, 2017 |
| D-MN | Collin C. Peterson | Feb 1, 2017 | |
| D-AZ | Tom O'Halleran | Feb 2, 2017 | |
| R-KY | Brett Guthrie | Feb 3, 2017 | |
| D-FL | Darren Soto | Feb 9, 2017 | |
| D-TX | Henry Cuellar | Feb 9, 2017 | |
| D-GA | Sanford D. Bishop, Jr. | Feb 9, 2017 | |
| D-MN | Timothy J. Walz | Feb 9, 2017 | |
| D-FL | Charlie Crist | Mar 7, 2017 | |
| D-IL | Bradley Scott Schneider | Mar 24, 2017 | |
| R-NE | Don Bacon | Apr 27, 2017 | |
| R-NE | Jeff Fortenberry | May 1, 2017 | |
| R-PR | Jenniffer González-Colón | May 24, 2017 | |
| D-NJ | Josh Gottheimer | Jun 2, 2017 | |
| R-MT | Greg Gianforte | Feb 6, 2018 | |
| R-CA | Stephen Knight | Feb 6, 2018 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Jan 30, 2017 |
| Health Subcommittee | Referred Feb 3, 2017 |
Actions 3
Everything that happened, newest first.
- Feb 3, 2017Referred to the Subcommittee on Health.
- Jan 30, 2017Introduced in House
- Jan 30, 2017Referred to the House Committee on Energy and Commerce.
In the Congressional Record 2
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
| Where | In the Record | Members | Date |
|---|---|---|---|
| House | Debate and remarks H5481 | Kurt Schrader D-OR | Jul 12, 2017 |
| House | Debate and remarks H1401 | Gus M. Bilirakis R-FL | Mar 1, 2017 |
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 163, no. 15, January 30, 2017, page H746.
Printed hearings 1
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| Serial No. 115-10 | EXAMINING FDA'S GENERIC DRUG AND BIOSIMILAR USER FEE PROGRAMS142 pages | Energy and Commerce Committee | Mar 2, 2017 |
Related bills 2
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 297 | Increasing Competition in Pharmaceuticals Act | Related bill | Feb 2, 2017 |
| HR 4784 | Lower Drug Costs through Competition Act | Reintroduction of | Mar 18, 2016 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To increase competition in the pharmaceutical industry.
- Short Titles as Introduced
- Lower Drug Costs through Competition Act
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Jan 30, 2017Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.